Search Results - "van Baal PHM"

P71 The Development of a Flexible and Easy to Tailor Disease Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma by Combining Trial and Real-World Data

de Groot, S, Blommestein, HM, Leeneman, B, Uyl-De, Groot CA, Haanen, JBAG, Suijkerbuijk, KPM, Aarts, M.J.B., van den Berkmortel, FWPJ, Blank, CU, Boers-Sonderen, MJ, van den Eertwegh, AJM, de Groot, JWB, Hospers, GAP, Kapiteijn, E, de Meza, MM, Piersma, D, van Rijn, RS, Stevense-den Boer, MAM, van der Veldt, AAM, Vreugdenhil, G, Wouters, MWJM, Franken, M, van Baal, PHM

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Benefits beyond health in the willingness to pay for a quality-adjusted life-year.

de Vries LM; Erasmus School of Health Policy and Management, Department of Health Economics, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands. l.m.devries@eshpm.eur.nl., Brouwer WBF; Erasmus School of Health Policy and Management, Department of Health Economics, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands., van Baal PHM; Erasmus School of Health Policy and Management, Department of Health Economics, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.

Journal Article , 2025

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.

de Groot S; Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, The Netherlands.; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, The Netherlands., Blommestein HM; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, The Netherlands., Leeneman B; Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, The Netherlands.; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, The Netherlands., Uyl-de Groot CA; Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, The Netherlands.; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, The Netherlands., Haanen JBAG; Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Wouters MWJM; Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., Aarts MJB; Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Center Sittard, Sittard-Geleen, The Netherlands., Blokx WAM; Department of Pathology, Division of Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands., Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., de Groot JWB; Isala Oncology Center, Isala, Zwolle, The Netherlands., Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., van Not OJ; Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Veldt AAM; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands., Suijkerbuijk KPM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., van Baal PHM; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, The Netherlands.

Journal Article , 2025

Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands.

de Vries LM; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, the Netherlands. Electronic address: l.m.devries@eshpm.eur.nl., Kellerborg KM; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, the Netherlands., Brouwer WBF; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, the Netherlands., van Baal PHM; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, the Netherlands.

Journal Article; Research Support, Non-U.S. Gov't , 2021

Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained.

Ratushnyak S; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Center of Healthcare Quality Assessment and Control, Ministry of Health of the Russian Federation, Moscow, Russia., Hoogendoorn M; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands., van Baal PHM; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address: vanbaal@eshpm.eur.nl.

Journal Article , 2019

A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.

Franken MG; Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, The Netherlands. Electronic address: franken@imta.eur.nl., Leeneman B; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, The Netherlands., Gheorghe M; Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands., Uyl-de Groot CA; Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, The Netherlands., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute- Antoni van Leeuwenhoek, Amsterdam, The Netherlands., van Baal PHM; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, The Netherlands.

Journal Article; Systematic Review; Network Meta-Analysis , 2019

Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.

de Vries LM; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands. l.m.devries@eshpm.eur.nl., van Baal PHM; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands., Brouwer WBF; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.

Journal Article , 2019

You Only Die Once: Accounting for Multi-Attributable Mortality Risks in Multi-Disease Models for Health-Economic Analyses.

Hoogenveen RT; National Institute of Public Health and the Environment, Expertise Center for Methodology and Information Services, Bilthoven, the Netherlands (RTH, HCB, PME)., Boshuizen HC; National Institute of Public Health and the Environment, Expertise Center for Methodology and Information Services, Bilthoven, the Netherlands (RTH, HCB, PME)., Engelfriet PM; National Institute of Public Health and the Environment, Expertise Center for Methodology and Information Services, Bilthoven, the Netherlands (RTH, HCB, PME)., van Baal PHM; Erasmus University Rotterdam, institute of Health Policy & Management, Rotterdam, Netherlands (PHMV).

Journal Article; Research Support, Non-U.S. Gov't , 2017